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Summary: 
 
Background – Atopic dermatitis (AD) is a common chronic inflammatory skin disease 
of humans and dogs. Regulatory T cells (Tregs) are essential controllers of immune 
homeostasis and have been shown to play a key role in human AD, even though 
frequencies of Tregs in atopic human patients vary greatly. Only two studies have 
reported Treg numbers in the peripheral blood of dogs with canine AD (CAD). 
Objectives – This study aimed to assess the numbers of circulating Tregs in healthy 
and atopic dogs, and to determine whether Treg numbers correlate with age, sex, 
disease severity or pre-treatment. 
Animals – Client-owned dogs including 14 healthy dogs and 35 dogs with CAD. 
Methods – Expression of Tregs in peripheral blood mononuclear cells was evaluated 
by flow cytometry. Tregs were phenotypically identified as T cells triple positive for 
CD4, CD25 and FoxP3. 
Results – The percentage of circulating CD4+CD25+FoxP3+ Tregs in atopic dogs was 
increased significantly compared to healthy dogs (mean 2.1% versus 1%, P = 0.002) 
and correlated with disease severity (Pruritus Scale: r = 0.48, P = 0.003; CADESI-04: 
r = 0.34, P = 0.044). No significant differences in age or sex were found 
in either group and pre-treatment had no influence on results for atopic dogs. 
Conclusions – Data suggest that, as in humans, CD4+CD25+FoxP3+ Tregs may 
contribute to the pathogenesis of CAD as indicated by an association between Treg 
frequency and disease severity. Further investigation is required to improve the 
understanding of the role of Tregs in atopic dogs. 
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Zusammenfassung: 
 
Hintergrund – Die atopische Dermatitis (AD) ist eine häufige chronisch-entzündliche 
Hauterkrankung bei Menschen und Hunden. Die regulatorischen T Zellen (Tregs) 
sind essentielle Kontrolleure der Homöostase des Immunsystems. Es konnte gezeigt 
werden, dass sie bei der AD des Menschen eine wichtige Schlüsselrolle 
einnehmen, obwohl die Anzahl der Tregs bei atopischen Menschen stark variieren. 
Es gibt bisher nur zwei Studien, die über die Anzahl der Tregs im peripheren Blut von 
Hunden mit caniner AD (CAD) berichten. 
Ziele – Das Ziel dieser Studie war die Erhebung der Anzahl zirkulierender Tregs bei 
gesunden und atopischen Hunden, und festzustellen, ob die Anzahl der Tregs mit 
dem Alter, dem Geschlecht und der Schwere der Erkrankung oder mit einer 
Vorbehandlung korrelierten. 
Tiere – Hunde im Privatbesitz, davon 14 gesunde Hunde und 35 Hunde mit CAD. 
Methoden – Die Exprimierung der Tregs in peripheren mononukleären Zellen des 
Blutes wurde mittels Flowzytometrie bestimmt. Die Tregs wurden phänotypisch als 
CD4, CD25 und FoxP3 positiv identifiziert. 
Ergebnisse – Der Prozentsatz der zirkulierenden CD4+CD25+FoxP3+ Tregs bei 
atopischen Hunden war im Vergleich zu gesunden Hunden signifikant erhöht 
(Durchschnitt 2,1% versus 1%, P = 0,002) und korrelierte mit der Schwere der 
Erkrankung (Juckreizskala: r = 0,48, P = 0,003; CADESI-04: r = 0,34, P = 0,044). Es 
bestanden in beiden Gruppen keine signifikanten Unterschiede abhängig vom Alter 
oder vom Geschlecht, auch hatte eine Vorbehandlung keinen Einfluss auf die 
Ergebnisse bei atopischen Hunden. 
Schlussfolgerungen – Die Ergebnisse weisen darauf hin, dass wie beim Menschen 
CD4+CD25+FoxP3+ Tregs an der Pathogenese der CAD teilhaben, was sich durch 
den Zusammenhang der Anzahl der Tregs und der Schwere der Erkrankung zeigte. 
Weitere Untersuchungen sind notwendig, um das Verständnis der Rolle der 
Tregs bei atopischen Hunden zu erweitern. 
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Background – Atopic dermatitis (AD) is a common chronic inflammatory skin disease of humans and dogs. Reg-
ulatory T cells (Tregs) are essential controllers of immune homeostasis and have been shown to play a key role in
human AD, even though frequencies of Tregs in atopic human patients vary greatly. Only two studies have
reported Treg numbers in the peripheral blood of dogs with canine AD (CAD).
Objectives – This study aimed to assess the numbers of circulating Tregs in healthy and atopic dogs, and to
determine whether Treg numbers correlate with age, sex, disease severity or pre-treatment.
Animals – Client-owned dogs including 14 healthy dogs and 35 dogs with CAD.
Methods – Expression of Tregs in peripheral blood mononuclear cells was evaluated by flow cytometry. Tregs
were phenotypically identified as T cells triple positive for CD4, CD25 and FoxP3.
Results – The percentage of circulating CD4+ CD25+ FoxP3+ Tregs in atopic dogs was increased significantly
compared to healthy dogs (mean 2.1% versus 1%, P = 0.002) and correlated with disease severity (Pruritus
Scale: r = 0.48, P = 0.003; CADESI-04: r = 0.34, P = 0.044). No significant differences in age or sex were found
in either group and pre-treatment had no influence on results for atopic dogs.
Conclusions – Data suggest that, as in humans, CD4+ CD25+ FoxP3+ Tregs may contribute to the pathogenesis
of CAD as indicated by an association between Treg frequency and disease severity. Further investigation is
required to improve the understanding of the role of Tregs in atopic dogs.
Introduction
Atopic dermatitis (AD) is a common, chronic and relapsing
inflammatory skin disease which affects several animal
species. Many clinical and pathogenetic similarities are
observed between human AD and canine AD (CAD).
Numerous studies have shown that AD involves both skin
barrier dysfunction and abnormal immunological
responses to allergens in genetically susceptible individu-
als.1,2 Human AD is associated with Th1/Th2 imbalances
and modified immune suppression induced by regulatory
T cells (Tregs).3,4
Tregs are an unique T-lymphocyte subgroup, represent-
ing up to 10% of all CD4+ T cells, and are divided into
different subsets which include naturally occurring thy-
mus-derived and peripherally induced Tregs.5,6 Each of
the two subpopulations can be phenotypically identified
by surface markers such as CD4 and CD25 as well as the
intranuclear transcription factor FoxP3, which define the
most studied and most commonly accepted pheno-
type.5–7 Tregs are known to prevent excessive immune
responses through their immunoregulatory properties
and therefore play a leading role in the maintenance of
immunological homeostasis.8,9 Thus, abnormalities in the
numbers or function of Tregs have been implicated in the
pathogenesis of allergic diseases.3,10–12
In humans, several studies have demonstrated altered
numbers of circulating Tregs in AD patients compared
with healthy controls.10,13–16 It is likely that Tregs play an
important role in CAD as well, given the immunological
similarities with its human counterpart. However, very lit-
tle is known about Tregs in atopic dogs. To the best of
the authors’ knowledge only three studies17–19 have
attempted to quantify canine Tregs and only one of these
evaluated Tregs in the peripheral blood of dogs with spon-
taneously occurring CAD.18 There was no difference in
circulating Tregs of atopic and healthy dogs at baseline;
an increase in the circulating Treg population of dogs with
CAD during allergen-specific immunotherapy was
reported.18 The presence of CD4+ CD25+ FoxP3+ Tregs
has recently been described in canine skin, although
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numbers were not significantly different between healthy
and atopic dogs.19
The goal of the present study was to assess the quan-
tity of circulating Tregs in dogs with CAD. Using three-col-
our flow cytometric analysis, we specifically evaluated
the percentage of CD4+ CD25+ FoxP3+ Tregs in periph-
eral blood mononuclear cells (PBMC) of atopic dogs com-
pared to healthy individuals. We hypothesized that a
statistically significant difference in Treg frequency would
be detected between the groups, providing new insight
into the potential role of Tregs in the pathogenesis of
CAD. We investigated the relationship between Treg fre-
quency and age, sex and recent immunomodulatory treat-
ment. We also explored whether Treg frequencies
correlate with clinical features of CAD as have been
described for human atopic diseases, such as the course
or severity of disease.10,16,20
Materials and methods
Animals and clinical evaluations
Thirty five atopic and 14 healthy client-owned dogs greater than
6 months of age were included in the study. Informed consent
was obtained from each dog owner before the study and all pro-
cedures were approved by the Cantonal Veterinary Office of Zur-
ich and conducted in accordance with guidelines established by
the Animal Welfare Act of Switzerland. Control samples were
obtained from healthy dogs with no histories of allergic skin dis-
eases. Vaccination within the previous month, treatment with
immunomodulatory agents, dermatitis of any type and diseases
known to affect the immune system were exclusion criteria for
healthy controls.
Dogs with CAD were recruited from the dermatology unit at the
Vetsuisse Faculty, University of Zurich. All atopic dogs had been
affected for a minimum of 3 months prior to recruitment and were
selected based on their medical histories, clinical features and fulfil-
ment of at least five of eight criteria.21 Differential diagnoses such as
ectoparasitic and infectious dermatoses were excluded by diagnostic
investigations including skin scrapings, cytological examination, bac-
terial and/or fungal culture when deemed appropriate, and lack of
response to therapeutic trials when needed.
Although adverse reaction to foods was not considered to be an
exclusion criterion, all subjects underwent a dietary elimination trial
of 6–8 weeks duration using novel ingredients or hydrolysed com-
mercial diets. Dietary re-challenge was performed in cases that
demonstrated improvement on the diet trial. None of the dogs
responded completely to this procedure, but seven demonstrated
partial improvements associated with dietary restriction.
Upon enrolment, severity of CAD was assessed using a validated
visual analog scale (VAS) for pruritus22 and a previously validated
scoring system (Canine Atopic Dermatitis Extent and Severity Index,
version 4; CADESI-04).23 Screening for environmental allergen sensi-
tivities was performed in all atopic dogs and consisted of intradermal
testing carried out with Greer allergens (Greer Veterinary Laborato-
ries, Lenoir, NC, USA) and/or allergen-specific IgE determination by
ELISA (HESKA inc., Fribourg, Switzerland). All subjects included in
the study demonstrated positive results with at least one of the two
tests. Positive reactions were evaluated and found to be compatible
with the clinical history of all of the dogs.
Clinical data collected included age, sex, course of disease (peren-
nial versus recurrent/seasonal signs), severity of CAD (pruritus,
CADESI-04) and recent treatment with immunomodulatory drugs
(glucocorticoids, ciclosporin and/or oclacitinib).
Immunomodulatory drugs were discontinued in the majority of
the subjects for a minimum of 2 weeks prior to blood sampling
and intradermal testing. However, nine subjects were still receiv-
ing immunomodulatory drugs at the time of sampling due to the
severity of their clinical signs. Such drugs had been reduced to
the minimum doses necessary during the two preceding weeks
(see Table 1 for details on agent and dosage). None of the
subjects had received allergen-specific immunotherapy. Oral
antimicrobial drugs and topical antibacterial or antifungal agents
were permitted up to the time of testing. Serological and intra-
dermal tests were performed after microbial and parasitic condi-
tions had been resolved, but when clinical signs of cAD were
still present.
Blood sampling and separation of PBMC
Approximately 2 mL of whole blood was collected from each control
or atopic dog by jugular or antebrachial cephalic venepuncture and
transferred into EDTA Vacuette tubes (Greiner Bio-One, Kremsm€un-
ster, Austria). Blood samples were stored at room temperature (RT)
and processed within 24 h after collection.
PBMC were isolated from whole blood using a standard density
gradient centrifugation by Histopaque-1077 g/mL (Sigma-Aldrich, St.
Louis, MO, USA) as described elsewhere.10,13 Anticoagulated blood
was layered onto Histopaque-1077, followed by centrifugation (700g)
for 25 min at RT. The layer of PBMC was collected from the inter-
face, washed and re-suspended in HBSS (Hank’s balanced salt solu-
tion, Gibco, Life Technologies; Carlsbad, CA, USA) supplemented
with 3% inactivated fetal calf serum (FCS) to establish cell count and
viability. The cell viability was determined by flow cytometry with
Guava ViaCount Flex (Merck Millipore; Billerica, MA, USA) and ran-
ged from 95 to 99%.
Cell staining and flow cytometric analysis of Tregs
A typical Treg phenotype based on the simultaneous expression of
CD4, CD25 and FoxP3 was analysed by flow cytometry according to
protocols described previously.7,24–27
In order to detect cell surface (CD4, CD25) and intranuclear
(FoxP3) markers, freshly isolated PBMC were stained with a com-
bination of dog-specific or cross-reactive fluorochrome-conjugated
monoclonal antibodies (mAbs) as follows: anti-canine CD4 fluores-
cein isothiocyanate (FITC) (clone YKIX302.9, AbD Serotec; Raleigh,
NC, USA), anti-canine CD25 phycoerythrin (PE) (clone P4A10, eBio-
science; San Diego, CA, USA) and cross-reactive anti-mouse/rat
FoxP3 eFluor660 (clone FJK-16s; eBioscience). Appropriate isotype
controls were performed for each experiment. FoxP3 staining was
conducted following the manufacturer’s instructions using the per-
meabilization buffer and fixation/permeabilization reagents provided
(FoxP3 Staining Set; eBioscience). In brief, freshly isolated PBMC
were suspended in 50 lL of HBSS supplemented with 3% FCS
(HBSS/3% FCS) and incubated directly with 5 lL of both anti-CD4
FITC and anti-CD25 PE for 30 min at 4°C in the dark. The optimal
working dilutions of mAbs were determined on a previously per-
formed antibody titration. Following surface staining, cells were
washed with HBSS/3% FCS for 5 min at RT (400g). The pellet
was then re-suspended in FoxP3 fixation/permeabilization working
solution and left at 4°C for 30 min in the dark. Cells were washed
consecutively with permeabilization buffer and probed for the
intranuclear marker FoxP3 with anti-FoxP3 eFluor660 at the con-
centration recommended by the manufacturer (0.5 lg per 105 to
108 cells), then allowed to interact for 30 min at 4°C in the dark.
Subsequently, the stained cells were washed twice with permeabi-
lization buffer and re-suspended in 200 lL HBSS/3% FCS for flow
cytometric analysis.
Flow cytometric acquisition was performed using a Guava easy-
Cyte 8HT Flow Cytometer (Merck Millipore) and interpreted using
the corresponding software GuavaSoft 2.5. In each sample, 10,000
events were analysed. Tregs in PBMC were identified as T cells tri-
ple-positive for CD4, CD25 and FoxP3. Initially, the fraction of lym-
phocytes was selected by typical forward- and side-scattered
properties28 and used for further analysis. Cells positive for CD4
were then gated on a FITC histogram and analysed for CD25 and
FoxP3. The number of Tregs was expressed as a percentage of the
total CD4+ T cell population.
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Data analyses
Tregs were defined as CD4+ CD25+ FoxP3+ cells for the purposes of
this study. However, data on the population of CD4+ FoxP3+ cells
were also collected for comparison, because the CD4+ FoxP3+ phe-
notype has been used for Treg characterization in several other stud-
ies.7,18,25–27 Correlation was determined between the two
populations.
The initial analyses compared the proportion of Tregs in atopic and
healthy dogs, and evaluated for correlation with age and sex. Subse-
quent analyses were restricted to the atopic group. The potential
effects of disease course and pre-treatment with immunomodulatory
drugs on Treg numbers were evaluated. Dogs with recurrent/sea-
sonal and perennial clinical signs, as well as treated and untreated
dogs, were compared. Correlations were also calculated between
Treg proportions and disease severity as assessed by CADESI-04
and the VAS. Finally, the impact of concurrent immunomodulatory
treatments (glucocorticoids, ciclosporin and oclacitinib) on these cor-
relations was investigated.
Statistical methods
Statistical analyses were performed using SPSS software v22.0 (IBM
Corp; Armonk, NY, USA). The means of the datasets, which were
not normally distributed as shown by the Kolmogorov–Smirnov test,
were compared using the nonparametric Mann–Whitney U-test for
independent samples. Correlation between populations of
CD4+ FoxP3+ and CD4+ CD25+ FoxP3+ cells was evaluated using
Spearman’s test. Correlations between normally distributed quantita-
tive variables were analysed using Pearson’s r-test because a linear
relationship between parameters was assumed. Statistical signifi-
cance was defined as P < 0.05.
Results
Animals and clinical data
Fourteen healthy (male/female ratio: 7/7; mean age:
5.5 years) and 35 atopic (m/f ratio: 21/14; mean age:
4.3 years) dogs were included. Table 1 shows signalment
and clinical data for the dogs with CAD. Most subjects
enrolled in the study demonstrated mild AD (CADESI-04
index 10–34: 19 dogs) or AD in remission (index <10: 9
dogs) according to the CADESI-04 severity categories.23 A
few subjects demonstrated moderate (index 35–59: 3
Table 1. Atopic dogs: clinical characteristics and percentage of canine regulatory T cells (Tregs)
Number Sex Age* Diagnosis
Course of
disease† Treatment‡ CADESI-04 Pruritus
% CD4+
CD25+
FoxP3+ Tregs
% CD4+
FoxP3+ T cells
1 mn 7 CAD 1 0 14 7 2.38 7.37
2 f 1 CAD 1 0 4 7 3.61 9.49
3 fn 8 CAD 1 0 18 5 4.06 9.46
4 fn 7 CAD/FA 1 0 2 3 2.02 3.98
5 mn 4 CAD 1 0 5 4 2.24 6.72
6 mn 6 CAD 0 0 25 3 2.66 5.10
7 f 1 CAD 1 1 7 3 2.70 7.03
8 fn 4 CAD 0 1 8 4 2.52 13.13
9 fn 6 CAD/FA 0 0 21 5 0.76 2.98
10 m 4 CAD 1 2 35 3 1.95 7.55
11 m 2 CAD/FA 1 3 19 8 3.55 9.48
12 mn 3 CAD 1 0 36 9 3.44 16.56
13 m 4 CAD 1 0 27 5 0.33 1.37
14 m 6 CAD 0 0 14 2 0.83 1.72
15 m 6 CAD 1 0 10 5 1.05 9.88
16 m 1 CAD 1 0 14 6 1.49 7.63
17 f 2 CAD 0 0 9 2 2.14 10.33
18 fn 2 CAD 0 0 9 1 1.27 8.04
19 fn 10 CAD 1 0 24 2 1.06 2.27
20 f 1 CAD/FA 1 0 10 10 0.93 3.57
21 mn 9 CAD 0 0 8 2 0.68 1.75
22 mn 4 CAD 1 1 19 4 0.92 3.13
23 fn 3 CAD 1 3 16 4 0.67 2.74
24 m 4 CAD/FA 0 0 16 2 0.65 3.02
25 mn 4 CAD 1 0 10 8 2.80 10.58
26 fn 7 CAD 1 3 4 8 4.79 27.25
27 f 6 CAD/FA 1 0 22 5 1.62 2.36
28 mn 3 CAD 1 0 62 10 2.38 29.19
29 m 8 CAD 1 0 89 7 3.65 30.29
30 m 1 CAD/FA 1 0 26 7 1.09 9.60
31 mn 2 CAD 1 0 10 1 2.02 8.58
32 mn 7 CAD 1 0 79 8 3.53 19.56
33 mn 3 CAD 1 1 117 10 3.75 20.56
34 m 2 CAD 1 1 35 6 2.32 5.80
35 m 1 CAD 1 0 11 6 1.62 2.84
CAD, canine atopic dermatitis; FA, food allergy; CADESI-04, Canine Atopic Dermatitis Extent and Severity Index, version 4; f, female; m, male;
n, neutered.
*Rounded.
†0 = seasonal/recurrent, 1 = permanent.
‡Immunomodulatory treatment during the 2 weeks preceding the test: 0, none; 1, prednisolone 0.5 mg/kg every other day (eod); 2, ciclosporin
5 mg/kg eod; 3, oclacitinib at the recommended dosage (0.4–0.6 mg/kg) once daily.
© 2015 ESVD and ACVD, Veterinary Dermatology, 27, 26–e9.28
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dogs) or severe (index ≥60: 4 dogs) disease. In total, index
scores ranged from 2 to 117 (mean = 24) on the CADESI-
04 scale which has a maximum score of 180.
Proportions of CD4+ CD25+ FoxP3+ and CD4+ FoxP3+
Tregs in PBMC
The proportion of circulating Tregs was defined as a
percentage of the total CD4+ T-cell population. The
gating strategy utilized and representative dot plots of
healthy and atopic dogs are presented in Figure 1.
In the PBMC of healthy individuals, Tregs defined
as CD4+ CD25+ FoxP3+ ranged from 0.22 to 2.48%
(mean 1%). In atopic dogs the same population
ranged from 0.33 to 4.79% (mean 2.1%; Table 1).
Statistically this difference was highly significant
(P = 0.002; Figure 2). It is worth noting that
despite this high level of significance, Treg proportions
from both study populations overlapped.
The proportion of CD4+ FoxP3+ cells was also signifi-
cantly greater in dogs with CAD (range 1.37–30.29%,
mean 9.2%; Table 1) than healthy dogs (range 0.94–
6.01%, mean 3.4%; P = 0.005). The proportions of
CD4+ FoxP3+ and CD4+ CD25+ FoxP3+ cells were
strongly correlated (r = 0.76, P < 0.001).
Figure 1. Gating strategy and flow cytometric evaluation of canine regulatory T cells (Tregs). (a) Peripheral blood mononuclear cells (PBMC) of
healthy and atopic dogs were stained with monoclonal antibodies against CD4, CD25 and intranuclear FoxP3. Initially the lymphocyte population
was gated based on side scatter (SSC) and forward scatter (FSC) distribution (gate 1). (b) Then, CD4+ cells were identified in a fluorescein isothio-
cyanate (FITC) histogram (gate 2) and used in subsequent analysis for CD25 and FoxP3 expression (dot plot CD25 versus FoxP3). Representative
dot plots are shown from a healthy dog (c) and a dog with atopic dermatitis (AD) (d). The numbers in the right upper quadrants represent the
respective percentages of CD4+ CD25+ FoxP3+ Tregs in gated CD4+ T-cell populations.
© 2015 ESVD and ACVD, Veterinary Dermatology, 27, 26–e9. 29
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Correlation of Treg percentage with clinical features
There were no statistical differences in Treg proportions
within the atopic and healthy groups in regard to age and
sex, nor was there an association with seasonality of clini-
cal signs or immunomodulatory drug therapy within the
atopic group. However, there was an association with dis-
ease severity: proportions of Tregs showed a moderate
positive correlation with pruritus (r = 0.48, P = 0.003)
and, to a lesser extent, with CADESI-04 scores (r = 0.34,
P = 0.044). When dogs that had received immunomodu-
latory drug therapy were removed from the analysis,
positive correlations were maintained: r = 0.39 for
pruritus (P = 0.047) and r = 0.41 for CADESI-04
(P = 0.038) (Figure 3).
Most of the atopic dogs had mild AD (n = 19) or AD in
remission (n = 9) and only few showed moderate (n = 3)
or severe (n = 4) category scores for the disease. We
also evaluated Treg percentage and CADESI-04 scores in
relation to the severity category. No significant relation-
ship was observed between severity groups.
Discussion
In the present study it was shown that the proportions of
FoxP3-expressing CD4+ CD25+ Tregs in the peripheral
blood of dogs with CAD was significantly increased com-
pared to healthy dogs. Furthermore, Treg levels corre-
lated with CADESI-04 and the VAS, suggesting that Tregs
are associated with disease severity.
Circulating Tregs have been evaluated in healthy dogs
in several previous works indicating that canine Treg
levels range from 0.7 to 7.2% (Table 2).7,18,24–27,29,30 The
results of these studies are sometimes difficult to com-
pare because of methodological differences such as vari-
ation in antibodies, gating strategies and Treg definitions
(CD4+ CD25+, CD4+ FoxP3+ or CD4+ CD25+ FoxP3+
cells). Currently, Tregs in dogs are generally defined by
the simultaneous expression of the markers CD4, CD25
and FoxP3.7,19,29 In order to compare our results with
those of previously published studies,7,18,25–27,29,30 we
also analysed populations of CD4+ FoxP3+ cells. In our
study, the frequency of these two populations of Tregs in
healthy dogs was generally consistent with the corre-
sponding values in previous works (Table 2).
We also found that the proportion of
CD4+ CD25+ FoxP3+ cells was markedly lower than the
CD4+ FoxP3+ cell population, although the correlation
between the two populations was strong and consistent
with that demonstrated in previous studies.7,26,29 In our
dataset only 30% of CD4+ FoxP3+ cells were also
CD25+, which is in accordance with a previous study.26
The difference between the two populations suggests
that the use of triple staining may be viewed as a more
precise definition of Tregs. However, this observation
may also raise the question as to what type of cells the
CD25 CD4+ FoxP3+ population truly represents. There
are two possible explanations. First, they could constitute
activated nonregulatory T cells because both CD25 and
FoxP3 can be expressed in naive CD4+ T cells upon acti-
vation.31 Second, they could represent Tregs in an “inac-
tive” state. It has been demonstrated that CD25 on Tregs
is fully labile, thus CD4+ CD25 FoxP3+ cells may be able
to act as a peripheral reservoir for “active”
CD4+ CD25+ FoxP3+ Tregs upon immune activation.32
Our results in dogs with CAD may be compared with
two prior studies. One study found that the percentage of
CD4+ FoxP3+ Tregs in healthy individuals was similar to
those in our study, but in contrast to our results, reported
that atopic dogs did not differ from healthy dogs.18 The
second study was carried out on experimentally chal-
lenged atopic beagles in which Tregs were defined as
CD4+ CD25+.17 This study reported results similar to our
atopic group. To the best of the authors’ knowledge, our
study is the first to compare Tregs in the peripheral blood
of healthy and atopic dogs by using simultaneous triple-
positive cells to define the Treg phenotype. Our results
mirror those of numerous reports in humans where
increased numbers of circulating Tregs have been
described for AD patients compared with healthy con-
trols.10,14–16 Two of these studies also demonstrated that
Tregs correlate with disease severity.10,16 Others
detected decreased13 or similar33 Treg numbers in AD
patients. The reasons for these inconsistent findings
remain speculative, but may be associated with the use
of variable definitions of Tregs and the existence of differ-
ent Treg subsets, such as thymus derived (tTregs) or
peripherally generated (pTregs) cells.34 The various
results may also be related to age differences, course of
disease, stage of the immune response, disease severity
or concurrent/prior therapies.
Human studies have indicated that Treg numbers
decline with age and that lifelong changes in Treg cell
subsets may be observed.31,35 In three studies evaluating
mainly adult patients with AD (the mean ages were 27,
27.1 and 42 years), increased numbers of circulating
Tregs were demonstrated compared to healthy con-
trols.10,14,15 However, one study enrolling children (mean
age 7.8 years) showed significantly lower frequencies of
Tregs in atopic patients.13 Our study did not demonstrate
Figure 2. Comparison of percentage of canine regulatory T cells
(Tregs) between atopic and healthy dogs. The percentage of
CD4+ CD25+ FoxP3+ Tregs in gated CD4
+ T cells was significantly
increased (mean 2.1% versus 1%) in peripheral blood of dogs with
atopic dermatitis (AD) (n = 35) compared with healthy controls
(n = 14). Results are presented as box plots with minimum, maxi-
mum, median and 25th/75th percentiles. A nonparametric Mann–
Whitney U-test was used for comparison between both groups
(P = 0.002).
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Figure 3. Correlation between percentage of canine regulatory T cells (Tregs) of atopic dogs and their disease severity. (a) The percentage of
CD4+ CD25+ FoxP3+ Tregs in gated CD4+ T cells of dogs with atopic dermatitis ( AD) (n = 35) was correlated positively with a Visual Analog Scale
for pruritus (r = 0.48, P = 0.003) and (b) to a minor degree, with Canine Atopic Dermatitis Extent and Severity Index (CADESI)-04 scores (r = 0.34,
P = 0.044). (c, d) The removal of dogs treated with immunomodulatory drugs (n = 9) from the group resulted in modified correlations (c) between
Tregs and pruritus (r = 0.39, P = 0.047), and (d) between Tregs and CADESI-04 (r = 0.41, P = 0.038). Pearson’s r-test was used for correlation
analyses.
Table 2. Percentage of canine regulatory T cells (Tregs) in peripheral blood of dogs – comparison of published studies
Year of publication Reference no. Treg definition No. of healthy/atopic % Tregs in healthy dogs % Tregs in atopic dogs
2007 25 CD4+ FoxP3+ 10/0 4.3
2008 18 CD4+ FoxP3+ 25/53 4.84 4.94
2009 30 CD4+ FoxP3+ 9/0 4.04
2009 27 CD4+ FoxP3+ 4/0* 1.08–2.65
2009 17 CD4+ CD25+ 0/6† 1.2–2.1
2010 7 CD4+ FoxP3+ 39/0 2.63**
CD4+ CD25+ 1.98**
CD4+ CD25+ FoxP3+ 0.98**
2010 24 CD4+ CD25+ 2/0‡ 7.2
2011 29 CD4+ FoxP3+ 11/0§ 2.8**
CD4+ CD25+ FoxP3+ 0.8**
2011 26 CD4+ FoxP3+ 12/0¶ 3.4
CD4+ CD25+ FoxP3+ 5/0¶ 0.7
2015 This study CD4+ FoxP3+ 14/35 3.4 9.2
CD4+ CD25+ FoxP3+ 1 2.1
The mean percentage of Tregs is given, unless otherwise indicated.
*Specific pathogen-free dogs.
†Experimental model, before and after challenge, previously sensitized beagles.
‡Exclusively beagles and beagle mixed breeds, immunomagnetically selected with CD3.
§Exclusively beagles.
¶Exclusively greyhounds and beagles aged between 12 and 30 months.
**Median.
© 2015 ESVD and ACVD, Veterinary Dermatology, 27, 26–e9. 31
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a significant correlation with age, but this might be related
to the fact that the relative age of onset of AD is greater
in dogs than in people.
Besides age, the course of disease may have an impact
as human patients with persistent allergic airway disease
had more Tregs than those with intermittent disease.20 In
our study we did not find a statistical difference in Treg
proportions between CAD subjects with seasonal/recur-
rent and perennial clinical signs. However, the possibility
that the high proportion of Tregs present in our cohort
could be related to the chronic nature of the disease can-
not be excluded, and it is possible that the proportion
would be different in cases of more acute onset.
It is also possible that Treg populations change during
AD development, depending on the stage of the immune
response and possibly related to a dynamic redistribution
between skin and peripheral blood. One study analysed
peripherally circulating Tregs in humans with AD at inter-
vals of 1–2 months and demonstrated decreases in Treg
frequency as skin lesions improved, suggesting migration
to the affected skin.10 However, we are not aware of
existing data to support a similar hypothesis in the dog. It
would be interesting to compare canine Treg populations
in PBMC and inflamed skin, and to sequentially track
these proportions during AD development.
Our study demonstrated a moderate but statistically
significant correlation between Treg numbers and dis-
ease severity, which has also been observed in several
studies of atopic humans.10,16,20,36 There are several pos-
sible explanations for this apparent paradox. First, the
higher proportion of Tregs might represent a subset of
pTregs generated by conversion from activated effector
or memory CD4+ T cells5 during repeated or prolonged
allergen stimulation and skin inflammation as part of the
immune response. It has been demonstrated in humans
that in addition to tTregs, the phenotype
CD4+ CD25+ FoxP3+ can also be adopted by pTregs;6
however, it is unknown whether this phenomenon occurs
in dogs. It is also possible that high numbers of
CD4+ CD25+ FoxP3+ cells represent either tTregs and
are a consequence of proliferated pre-existing tTregs or
upregulated conventional T cells with a Treg phenotype,5
but without regulatory function. This latter option would
also explain the persistence of the allergic disease
despite the upregulation of Tregs in our canine subjects.
Indeed, it remains unclear why the increased Tregs in
our cohort appear to have no protective effect on clinical
signs. Apart from the aforementioned hypotheses, a
functional insufficiency of Tregs as demonstrated in aller-
gic asthmatic children37 could be postulated. However,
other studies have found no evidence of an impaired sup-
pressive activity of Tregs in human allergic dis-
eases,15,20,33,36 even when (in accordance with our
results) high Treg numbers were found.15 Interestingly,
when dogs treated with immunomodulatory drugs were
removed from the analysis, the correlation between
CADESI-04 score and Treg numbers improved. A possible
explanation could be that treated dogs have a lower index
of severity but that high Tregs are still present in the circu-
lation. However, previous work in humans suggests that
Tregs rapidly decrease in the face of clinical improve-
ment.10,38 Alternatively, immunomodulatory treatment
may increase the number of Tregs which, in turn, con-
tribute to the improvement of the severity index. In asth-
matic humans, glucocorticoids have been shown to
increase FoxP3 expression39 and Treg percentages.40
However, we did not detect any significant difference in
the proportions of Tregs between treated and untreated
atopic dogs.
The variable findings between studies may imply that
the role of Tregs in AD is complex and that the patho-
genetic mechanisms of Tregs are possibly not the same
in all allergic patients. Functional and/or quantitative differ-
ences are just as conceivable as the possibility that differ-
ent Treg subtypes or single populations could be
affected. The great overlap between both the healthy and
atopic group might be an indication not only that the abso-
lute Treg number plays a role, but also the individual ratio
of Tregs to nonregulatoy (effector) T cells can in every
allergic patient.
In summary, our preliminary study demonstrates that
the proportion of circulating Tregs is increased in atopic
dogs, and correlates with severity. These findings suggest
that Tregs may be involved in the pathogenesis of CAD.
Additional studies will be necessary to determine which
subtypes of Tregs are involved, whether they are also
modified in acute cases (at the onset of clinical disease)
and if increased numbers are associated with high expres-
sion of regulatory cytokines such as IL-10 or TGF-b (as
functional markers for Treg suppressive capacity). It
would also be interesting to follow the change of this pop-
ulation of T cells – both in peripheral blood and atopic skin
– during natural development of the disease and over the
course of successful (or unsuccessful) treatment for CAD.
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Resume
Contexte – La dermatite atopique (AD) est une maladie cutanee inflammatoire chronique frequente de
l’homme et du chien. Les cellules T regulatrices (Tregs) sont essentielles dans le contro^le de l’homeostasie
immunitaire et jouent un ro^le cle dans l’AD de l’homme me^me si la frequence de Tregs chez les patients
atopiques humains varie de facon importante. Seules deux etudes ont etudiees le nombre de Tregs dans le
sang peripherique du chien atopique (CAD).
Objectifs – Cette etude a pour objectif d’estimer le nombre de Tregs circulants chez le chien sains et atopi-
que et de determiner si le nombre de Treg correle avec l’a^ge, le genre, la severite de la maladie ou le
pretraitement.
Sujets – Des chiens de proprietaires dont 14 chiens sains et 35 chiens atopiques.
Methodes – L’expression des cellules mononuclees Tregs dans le sang peripherique a ete evaluee par
cytometrie de flux. Les Tregs ont ete phenotypiquement identifies comme cellules T triplement positives
pour CD4, CD25 et FoxP3.
© 2015 ESVD and ACVD, Veterinary Dermatology, 27, 26–e9. 33
CD4+ CD25+ FoxP3+ Tregs in atopic dogs
10
Resultats – Le pourcentage de Tregs CD4+ CD25+ FoxP3+ circulants chez les chiens atopiques etait aug-
mente significativement compare aux chiens sains (moyenne 2.1% versus 1%, P = 0.002) et correlait avec
la severite de la maladie (echelle de prurit: r = 0.48, P = 0.003; CADESI-04: r = 0.34, P = 0.044). Aucune
difference significative d’a^ge ou de genre n’a ete trouvee dans chaque groupe et le pretraitement n’avait
aucune influence sur les resultats des chiens atopiques.
Conclusions – Les donnees suggerent que, comme pour l’AD humaine, les Tregs CD4+ CD25+ FoxP3+
peuvent contribuer a la pathogenie de la DAC telle que l’indique l’association entre la frequence de Treg et
la severite de la maladie. De plus amples investigations sont necessaires pour ameliorer la comprehension
du ro^le des Tregs dans la dermatite atopique.
Resumen
Introduccion – La dermatitis atopica (AD) es una enfermedad cronica inflamatoria de la piel comun en
seres humanos y perros. Los linfocitos T reguladores (Tregs) son componentes esenciales del control de la
homeostasis inmunitaria y han demostrar tener un papel clave de la dermatitis atopica humana, incluso
aunque la frecuencia de los linfocitos T reguladores en los pacientes humanos con atopia varıan enorme-
mente. Solo dos estudios han publicado los numeros de linfocitos T reguladores en la sangre periferica de
perros con dermatitis atopica canina (CAD).
Objetivos – este estudio esta enfocado a evaluar los numeros de linfocitos T reguladores en perros sanos
y perros con atopia y determinar si los numeros de linfocitos T reguladores se correlacionan con la edad,
sexo, severidad de la enfermedad o tratamiento previo.
Animales – perros de propietarios privados incluyendo 14 perros sanos y 35 perros con atopia.
Metodos – la expresion de linfocitos T reguladores en celulas mononucleares de sangre periferica se
evaluo mediante citometrıa de flujo. Los linfocitos T reguladores fueron tıpicamente identificados como
celulas triples positivas para CD4, CD25, y FoxP3.
Resultados – el porcentaje de linfocitos T reguladores CD4+, CD25+ FoxP3+ en perros atopicos se incre-
mento significativamente comparado con los perros sanos (media 2,1% frente a 1%, P = 0,002), y se corre-
laciono con la severidad de la enfermedad (escala de prurito: r = 0,48, P = 0,003; CADESI-04: r= 0,34, P =
0,044). No hubo diferencias significativas en edad basados en edad o sexo en ningun grupo y el tratamiento
previo no tuvo influencia en los resultados en perros topicos.
Conclusion e importancia clınica – los datos sugieren que, al igual que en humanos, los linfocitos T regu-
ladores CD4+, CD25+ FoxP3+ pueden contribuir a la patogenesis de la dermatitis atopica canina tal y como
indica la asociacion entre la frecuencia de linfocitos T reguladores y la severidad de la enfermedad. Se
requieren mas investigaciones para mejorar la comprension del papel de los linfocitos T reguladores en per-
ros atopicos.
Zusammenfassung
Hintergrund – Die atopische Dermatitis (AD) ist eine h€aufige chronische entz€undliche Hauterkrankung bei
Menschen und Hunden. Die regulatorischen T Zellen (Tregs) sind essentielle Kontrolleure der Hom€oostase des
Immunsystems und es konnte gezeigt werden, dass sie bei der AD des Menschen eine wichtige Schl€ussel-
rolle spielen, obwohl die Anzahl der Tregs bei atopischenMenschen stark variieren. Es gibt bisher nur zwei Stu-
dien, die €uber die Anzahl der Tregs im peripheren Blut von Hunden mit caniner AD (CAD) berichten.
Ziele – Das Ziel dieser Studie war eine Erhebung der Anzahl der zirkulierenden Tregs bei gesunden und atopi-
schen Hunden, und festzustellen, ob die Anzahl der Tregs mit dem Alter, dem Geschlecht und der Schwere
der Erkrankung oder mit einer Vorbehandlung korrelierten.
Tiere – Hunde im Privatbesitz, davon 14 gesunde Hunde und 35 Hunde mit CAD.
Methoden – Die Exprimierung der Tregs in peripheren mononukle€aren Zellen des Blutes wurde mittels Flow-
zytometrie bestimmt. Die Tregs wurden ph€anotypisch als CD4, CD25 und FoxP3 positiv identifiziert.
Ergebnisse –Der Prozentsatz der zirkulierenden CD4+CD25+FoxP3+ Tregs bei atopischen Hundenwar im Ver-
gleich zu gesunden Hunden signifikant erh€oht (Durchschnitt 2,1% versus 1%, P=0,002) und korrelierte mit der
Schwere der Erkrankung (Juckreizskala: r=0,48, P=0,003; CADESI-04: r=0,34, P=0,044). Es bestanden in bei-
den Gruppen keine signifikanten Unterschiede zwischen dem Alter oder dem Geschlecht, eine Vorbehandlung
hatte keinen Einfluss auf die Ergebnisse bei atopischen Hunden.
Schlussfolgerungen – Die Ergebnisse weisen darauf hin, dass wie beim Menschen CD4+CD25+FoxP3+
Tregs an der Pathogenese der CAD teilhaben, was sich durch den Zusammenhang der Anzahl der Tregs und
der Schwere der Erkrankung zeigte. Eine weitere Untersuchung ist n€otig, um das Verst€andnis der Rolle der
Tregs bei atopischen Hunden zu erweitern.
要約
背景 – アトピー性皮膚炎(AD)はヒトおよびイヌの一般的な慢性炎症性皮膚疾患である。制御性T細胞(Tregs)は免
疫ホメオスタシスの必須制御要素で、ヒトADにおいてTregsの頻度は患者により大きく異なっているにも関わらず、重要
な役割を果たしていることが示されている。イヌAD(CAD)のイヌの末梢血におけるTregs数は2つの研究でしか報告されて
いない。
Hauck et al.
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目的 – この研究は健康なイヌとアトピー犬における循環中Tregsの数を評価すること、およびTregs数が年齢、性
別、疾患の重症度あるいは治療前と関係しているのかを明らかにすることを目的とした。
供与動物 – 14頭の健康な飼い犬と35頭のCADの飼い犬。
方法 – 末梢血の単核細胞におけるTregsの発現をフローサイトメトリーにより評価した。TregsはCD4、CD25および
FoxP3の3つが陽性のT細胞として表現型を特定した。
結果 – アトピー犬における循環中CD4+ CD25+ FoxP3+ Tregsの割合は健常犬と比較し有意に増加し(平均2.1% 対
1%, P = 0.002)、疾患重症度と相関していた(そう痒スケール: r = 0.48, P = 0.003; CADESI-04: r = 0.34, P =
0.044)。年齢あるいは性別にはいずれの群においても有意差は認められず、アトピー犬で治療前であることは結果に
影響しなかった。
結論 –データからヒトと同様、CD4+ CD25+ FoxP3+ Tregsは、Tregs頻度および重症度の間の関係が示しているよう
にCADの病因の一因であるかもしれない。アトピー犬におけるTregsの役割への理解を深めるために、さらなる調査が
必要とされる。
摘要
背景 – 异位性皮炎是种在人和犬上均常见的慢性炎性皮肤病。调节性T细胞(Treg)是基本的免疫稳态控制
器,并已认定在人AD上起重要作用,尽管人异位性患者Treg出现的频率差异很大。只有两篇研究报告过AD患
犬外周血中Treg数量。
目的 – 本次研究目的为评估健康犬和AD患犬的循环Treg数量,并确定Treg数量分别与年龄、性别、疾病严
重程度或治疗是否有关。
动物 – 来自动物主人的14只健康犬和35只AD患犬。
方法 – 使用流式细胞术评估Treg在外周血单核细胞中的表达。具有CD4、CD25和FoxP3三重阳性反应表型
的T细胞,被认为是Treg。
结果 –异位性皮炎患犬循环中CD4+ CD25+ FoxP3+Tregs比健康犬显著增多(平均值2.1%比 1%, P = 0.002),
并与疾病严重度有关(瘙痒评分: r = 0.48, P = 0.003; CADESI-04: r = 0.34, P = 0.044)。其与年龄、性别没有
显著关联,异位性皮炎患犬治疗后无明显改变。
结论与临床意义 – 数据显示 ,与人类一样 ,通过Tr e g频率和疾病的严重程度间的关联 ,可知
CD4+CD25+FoxP3+Tregs参与CAD的发病机理。需要进一步调查,帮助我们提高对犬异位性皮炎中Treg作
用的认识。
CD4+ CD25+ FoxP3+ Tregs in atopic dogs
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